Telix Pharmaceuticals director files Form 3

Telix Pharmaceuticals Ltd filed an initial Form 3 identifying David N. Gill as a director of the company.

Rhea-AI Filing Summary

Telix Pharmaceuticals Ltd filed an initial Form 3 identifying David N. Gill as a director of the company. The filing’s transaction summary shows no reported purchases, sales, exercises, gifts, or other share movements, and net buy/sell activity is neutral in this excerpt.

Key Figures

Buy transactions: 0 transactions Sell transactions: 0 transactions Net buy/sell shares: 0 shares +1 more

4 metrics

Buy transactions 0 transactions Form 3 transactionSummary buyCount

Sell transactions 0 transactions Form 3 transactionSummary sellCount

Net buy/sell shares 0 shares Form 3 transactionSummary netBuySellShares

Net buy/sell direction neutral Form 3 transactionSummary netBuySellDirection

Key Terms

reporting person, ten percent owner, transactionSummary

3 terms

reporting person financial

""reportingPersons": [ { "name": "GILL DAVID N""

ten percent owner financial

""is_ten_percent_owner": 0"

transactionSummary financial

""transactionSummary": { "buyCount": 0, "sellCount": 0"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Telix Pharmaceuticals Ltd (TLX) Form 3 show about David N. Gill?

The Form 3 lists David N. Gill as a director of Telix Pharmaceuticals Ltd. In this excerpt, the transaction summary shows no reported share purchases, sales, exercises, gifts, or other movements, and indicates a neutral net buy/sell direction.

Does the Telix Pharmaceuticals (TLX) Form 3 show any insider trading activity?

In this excerpt, the Form 3 transaction summary shows no insider trading activity. Buy, sell, acquire, dispose, exercise, gift, tax withholding, and restructuring counts are all zero, and net buy/sell direction is listed as neutral.

Is David N. Gill a ten percent owner of Telix Pharmaceuticals Ltd (TLX)?

The Form 3 indicates that David N. Gill is not a ten percent owner of Telix Pharmaceuticals Ltd. He is identified as a director, with the ten percent owner flag set to zero in the reporting person details.

What does the transactionSummary in the Telix (TLX) Form 3 indicate?

The transactionSummary shows zero counts and share amounts for buys, sells, exercises, gifts, tax withholding, restructuring, and derivative transactions. It also reports netBuySellShares of 0 and a neutral netBuySellDirection for this Form 3 excerpt.

Are any derivative positions disclosed in the Telix Pharmaceuticals (TLX) Form 3 excerpt?

The derivativeSummary section in this Form 3 excerpt is empty. This means no derivative positions, such as options or other derivative securities, are listed here for David N. Gill in connection with his role as a director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/18/2026 - 06:34 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

GILL DAVID N

(Last) (First) (Middle)

C/O TELIX PHARMACEUTICALS LTD

55 FLEMINGTON RD

(Street)

NORTH MELBOURNE 3051

(City) (State) (Zip)

AUSTRALIA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/11/2026

3. Issuer Name and Ticker or Trading Symbol
Telix Pharmaceuticals Ltd [ TLX ]

3a. Foreign Trading Symbol
[TLX]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Ex. 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Oliver Newman, on behalf of David Gill	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)